#USA #Viking Therapeutics #GLP-1 #CordenPharma

CordenPharma and Viking Therapeutics: A Strategic Partnership for GLP-1 Peptides

In the ever-evolving landscape of biotech and pharmaceuticals, CordenPharma and Viking Therapeutics have taken a significant step forward by entering into a long-term strategic partnership aimed at advancing the supply of GLP-1 peptides. On March 11, 2025, CordenPharma announced this partnership, highlighting its commitment to supporting Viking's innovative candidate, VK2735, a dual GLP-1/GIP receptor agonist designed to address metabolic and endocrine disorders.

Integrated Supply Chain for GLP-1 Therapies

As part of this collaboration, CordenPharma will deliver comprehensive development and manufacturing services for VK2735, providing integrated support from active pharmaceutical ingredient (API) through to the final drug product. This includes both subcutaneous injectable and oral solid dosage formulations, showcasing CordenPharma's manufacturing capabilities tailored specifically for the needs of complex peptide therapeutics.

CordenPharma's expertise lies in large-scale peptide production, which is essential for ensuring a reliable supply chain for pharmaceutical companies. Their facilities are equipped to handle sterile injectables and solid oral forms, thus enabling a seamless transition from development to market launch, which is critical for the success of VK2735.

Addressing the Market Demands

Through this partnership, CordenPharma is set to leverage its extensive global manufacturing network, ensuring that production meets both clinical and commercial demand for VK2735. The dual receptor agonist has significant potential in treating obesity and improving metabolic health, making it a highly sought-after therapy in today's health landscape.

Dr. Michael Quirmbach, CEO of CordenPharma, emphasized the importance of this partnership, expressing pride in supporting Viking Therapeutics with an integrated approach that enhances the availability of GLP-1 peptide therapies. The collaboration aims not only to meet market needs but also to positively impact patient outcomes by facilitating access to these innovative treatments.

CordenPharma’s Expertise and Global Footprint

Established as a leading Contract Development and Manufacturing Organization (CDMO), CordenPharma focuses on providing tailored solutions for biotechnology and pharmaceutical innovators. Their scientific foundation and expertise in various therapeutic modalities enable them to offer significant value across the pharmaceutical supply chain. The entire group comprises 11 manufacturing sites across Europe and North America, which collectively generated sales of €854 million in the 2024 fiscal year.

The strategic acquisition by Astorg in 2022 has further strengthened CordenPharma’s leadership in peptide CDMO, allowing the company to accelerate its growth and innovation in drug development. CordenPharma's commitment to high-quality manufacturing and its strategic focus on the development of peptides, oligonucleotides, and other complex drugs makes it an invaluable partner for organizations like Viking Therapeutics.

The Future of GLP-1 Therapies

The collaboration between CordenPharma and Viking Therapeutics can potentially pave the way for breakthroughs in the treatment of metabolic disorders. By streamlining the path from development to market, the partnership is poised to improve the availability of groundbreaking GIP and GLP-1 therapies. As demand for effective treatments grows, this strategic alliance not only secures a reliable supply chain but also enhances patient care outcomes across the globe.

In conclusion, CordenPharma and Viking Therapeutics are exemplifying how strategic partnerships in the pharmaceutical industry can enhance the development and delivery of critical therapies. Through their collaborative efforts, both companies reaffirm their dedication to innovation and improving health solutions for patients everywhere.